TIME in Immunotherapy Combined With nCRT for Rectal Cancer
Status:
Not yet recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, prospective phase II clinical trial to evaluate the therapeutic and
prognostic implications of tumor immune microenvironment in the neoadjuvant immunotherapy
combined with chemoradiotherapy for patients with rectal cancer. A total of 100 patients will
be enrolled in this trial. The primary end point is the rate of pathological complete
response (pCR). The long-term prognosis and adverse effects will also be evaluated and
analyzed.